Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Aurora Cannabis Inc.NASDAQ: ACB

Research & Development · Q4 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q4 FY2026 research & development of CA$1.84M rose 134.6% year over year, ahead of the +35.4% change in trailing-twelve-month research & development. Sequentially, it rose 41.3% from the prior quarter. Over 3 fiscal years it compounded at +1.4% a year.

Context

  • Research & development amounted to 1.9% of revenue in FY2026, up 0.8 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +134.6% holds above the trailing-twelve-month pace of +35.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$1.84M+41.3% QoQ
Last fiscal yearMar 2026
CA$6.01M+63.6% YoY
LTMMar 2026
CA$4.98M+35.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+134.6%——
1 year+63.6%——
3-year CAGR+1.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2026
6.01M CAD
Year-over-year change
+63.6%
4-year CAGR
-12.8%

Research & Development vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.4% is the 3rd highest of 9, against a peer median of -15.0%.
  • Research & development amounts to 1.6% of revenue for ACB, versus a peer median of 5.5%.
ACB Competitors
Research & Development for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$88.26M USD-21.9%+29.1%24.4%
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M USD+36.9%+34.3%807.2%
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M USD-62.3%-19.9%171.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
OGIOrganigram Global Inc.LTM Mar 2026CA$10.02M CAD+9.4%—3.7%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$7.58M USD—+1.8%5.6%
LFMDLifeMD, Inc.LTM Mar 2026$7.53M USD-25.4%+35.2%3.4%
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.98M CAD+35.4%+1.4%1.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026$2.25M USD-8.0%-34.3%5.4%
CGCCanopy Growth CorporationLTM Mar 2026CA$0 CAD-100.0%—0.0%
HITIHigh Tide Inc.LTM Apr 2026CA$0 CAD——0.0%
Peer median (excluding ACB) —-15.0%+1.8%5.5%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.